aluates Reports

$ 0.0

Automative

Global Peptide Drugs for Metabolic Diseases Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-12O19203

BUY CHAPTERS

Global Peptide Drugs for Metabolic Diseases Market Research Report 2025

Code: QYRE-Auto-12O19203

Report

March 2025

Pages:75

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Peptide Drugs for Metabolic Diseases Market Size

The global market for Peptide Drugs for Metabolic Diseases was valued at US$ 42500 million in the year 2024 and is projected to reach a revised size of US$ 85620 million by 2031, growing at a CAGR of 10.6% during the forecast period.

Peptide Drugs for Metabolic Diseases Market

Peptide drugs play a crucial role in the treatment of metabolic diseases, particularly in diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). These drugs often mimic or regulate endogenous hormones, such as glucagon-like peptide-1 (GLP-1), insulin, and glucagon, to improve blood sugar control, regulate appetite, and enhance lipid metabolism. In recent years, GLP-1 receptor agonists (e.g., semaglutide) and insulin analogs (e.g., insulin glargine) have been widely used in clinical practice, significantly improving treatment outcomes. Furthermore, innovative peptide drugs are being developed to enhance efficacy, prolong half-life, and reduce side effects, making them a promising direction for future metabolic disease therapies.

North American market for Peptide Drugs for Metabolic Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptide Drugs for Metabolic Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Peptide Drugs for Metabolic Diseases include Novo Nordisk, AstraZeneca, Eli Lily, Sanofi, Huadong Medicine, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Peptide Drugs for Metabolic Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Drugs for Metabolic Diseases.

The Peptide Drugs for Metabolic Diseases market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide Drugs for Metabolic Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Peptide Drugs for Metabolic Diseases manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Peptide Drugs for Metabolic Diseases Market Report

Report Metric	Details
Report Name	Peptide Drugs for Metabolic Diseases Market
Accounted market size in year	US$ 42500 million
Forecasted market size in 2031	US$ 85620 million
CAGR	10.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Semaglutide Dulaglutide Insulin Glargine Insulin Aspart Liraglutide Others
Segment by Application	Diabetes Obesity Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, AstraZeneca, Eli Lily, Sanofi, Huadong Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Peptide Drugs for Metabolic Diseases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Peptide Drugs for Metabolic Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Peptide Drugs for Metabolic Diseases Market growing?

Ans: The Peptide Drugs for Metabolic Diseases Market witnessing a CAGR of 10.6% during the forecast period 2025-2031.

What is the Peptide Drugs for Metabolic Diseases Market size in 2031?

Ans: The Peptide Drugs for Metabolic Diseases Market size in 2031 will be US$ 85620 million.

Who are the main players in the Peptide Drugs for Metabolic Diseases Market report?

Ans: The main players in the Peptide Drugs for Metabolic Diseases Market are Novo Nordisk, AstraZeneca, Eli Lily, Sanofi, Huadong Medicine

What are the Application segmentation covered in the Peptide Drugs for Metabolic Diseases Market report?

Ans: The Applications covered in the Peptide Drugs for Metabolic Diseases Market report are Diabetes, Obesity, Others

What are the Type segmentation covered in the Peptide Drugs for Metabolic Diseases Market report?

Ans: The Types covered in the Peptide Drugs for Metabolic Diseases Market report are Semaglutide, Dulaglutide, Insulin Glargine, Insulin Aspart, Liraglutide, Others

1 Peptide Drugs for Metabolic Diseases Market Overview

1.1 Product Definition

1.2 Peptide Drugs for Metabolic Diseases by Type

1.2.1 Global Peptide Drugs for Metabolic Diseases Market Value Comparison by Type (2024 VS 2031)

1.2.2 Semaglutide

1.2.3 Dulaglutide

1.2.4 Insulin Glargine

1.2.5 Insulin Aspart

1.2.6 Liraglutide

1.2.7 Others

1.3 Peptide Drugs for Metabolic Diseases by Application

1.3.1 Global Peptide Drugs for Metabolic Diseases Market Value by Application (2024 VS 2031)

1.3.2 Diabetes

1.3.3 Obesity

1.3.4 Others

1.4 Global Peptide Drugs for Metabolic Diseases Market Size Estimates and Forecasts

1.4.1 Global Peptide Drugs for Metabolic Diseases Revenue 2020-2031

1.4.2 Global Peptide Drugs for Metabolic Diseases Sales 2020-2031

1.4.3 Global Peptide Drugs for Metabolic Diseases Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Peptide Drugs for Metabolic Diseases Market Competition by Manufacturers

2.1 Global Peptide Drugs for Metabolic Diseases Sales Market Share by Manufacturers (2020-2025)

2.2 Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Peptide Drugs for Metabolic Diseases Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Peptide Drugs for Metabolic Diseases, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Peptide Drugs for Metabolic Diseases, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Peptide Drugs for Metabolic Diseases, Product Type & Application

2.7 Global Key Manufacturers of Peptide Drugs for Metabolic Diseases, Date of Enter into This Industry

2.8 Global Peptide Drugs for Metabolic Diseases Market Competitive Situation and Trends

2.8.1 Global Peptide Drugs for Metabolic Diseases Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Peptide Drugs for Metabolic Diseases Players Market Share by Revenue

2.8.3 Global Peptide Drugs for Metabolic Diseases Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Peptide Drugs for Metabolic Diseases Market Scenario by Region

3.1 Global Peptide Drugs for Metabolic Diseases Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Peptide Drugs for Metabolic Diseases Sales by Region: 2020-2031

3.2.1 Global Peptide Drugs for Metabolic Diseases Sales by Region: 2020-2025

3.2.2 Global Peptide Drugs for Metabolic Diseases Sales by Region: 2026-2031

3.3 Global Peptide Drugs for Metabolic Diseases Revenue by Region: 2020-2031

3.3.1 Global Peptide Drugs for Metabolic Diseases Revenue by Region: 2020-2025

3.3.2 Global Peptide Drugs for Metabolic Diseases Revenue by Region: 2026-2031

3.4 North America Peptide Drugs for Metabolic Diseases Market Facts & Figures by Country

3.4.1 North America Peptide Drugs for Metabolic Diseases Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Peptide Drugs for Metabolic Diseases Sales by Country (2020-2031)

3.4.3 North America Peptide Drugs for Metabolic Diseases Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Peptide Drugs for Metabolic Diseases Market Facts & Figures by Country

3.5.1 Europe Peptide Drugs for Metabolic Diseases Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Peptide Drugs for Metabolic Diseases Sales by Country (2020-2031)

3.5.3 Europe Peptide Drugs for Metabolic Diseases Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Peptide Drugs for Metabolic Diseases Market Facts & Figures by Region

3.6.1 Asia Pacific Peptide Drugs for Metabolic Diseases Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Peptide Drugs for Metabolic Diseases Sales by Region (2020-2031)

3.6.3 Asia Pacific Peptide Drugs for Metabolic Diseases Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Peptide Drugs for Metabolic Diseases Market Facts & Figures by Country

3.7.1 Latin America Peptide Drugs for Metabolic Diseases Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Peptide Drugs for Metabolic Diseases Sales by Country (2020-2031)

3.7.3 Latin America Peptide Drugs for Metabolic Diseases Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Peptide Drugs for Metabolic Diseases Market Facts & Figures by Country

3.8.1 Middle East and Africa Peptide Drugs for Metabolic Diseases Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Peptide Drugs for Metabolic Diseases Sales by Country (2020-2031)

3.8.3 Middle East and Africa Peptide Drugs for Metabolic Diseases Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Peptide Drugs for Metabolic Diseases Sales by Type (2020-2031)

4.1.1 Global Peptide Drugs for Metabolic Diseases Sales by Type (2020-2025)

4.1.2 Global Peptide Drugs for Metabolic Diseases Sales by Type (2026-2031)

4.1.3 Global Peptide Drugs for Metabolic Diseases Sales Market Share by Type (2020-2031)

4.2 Global Peptide Drugs for Metabolic Diseases Revenue by Type (2020-2031)

4.2.1 Global Peptide Drugs for Metabolic Diseases Revenue by Type (2020-2025)

4.2.2 Global Peptide Drugs for Metabolic Diseases Revenue by Type (2026-2031)

4.2.3 Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Type (2020-2031)

4.3 Global Peptide Drugs for Metabolic Diseases Price by Type (2020-2031)

5 Segment by Application

5.1 Global Peptide Drugs for Metabolic Diseases Sales by Application (2020-2031)

5.1.1 Global Peptide Drugs for Metabolic Diseases Sales by Application (2020-2025)

5.1.2 Global Peptide Drugs for Metabolic Diseases Sales by Application (2026-2031)

5.1.3 Global Peptide Drugs for Metabolic Diseases Sales Market Share by Application (2020-2031)

5.2 Global Peptide Drugs for Metabolic Diseases Revenue by Application (2020-2031)

5.2.1 Global Peptide Drugs for Metabolic Diseases Revenue by Application (2020-2025)

5.2.2 Global Peptide Drugs for Metabolic Diseases Revenue by Application (2026-2031)

5.2.3 Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Application (2020-2031)

5.3 Global Peptide Drugs for Metabolic Diseases Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Peptide Drugs for Metabolic Diseases Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Novo Nordisk Peptide Drugs for Metabolic Diseases Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Company Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Peptide Drugs for Metabolic Diseases Sales, Revenue and Gross Margin (2020-2025)

6.2.4 AstraZeneca Peptide Drugs for Metabolic Diseases Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Eli Lily

6.3.1 Eli Lily Company Information

6.3.2 Eli Lily Description and Business Overview

6.3.3 Eli Lily Peptide Drugs for Metabolic Diseases Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Eli Lily Peptide Drugs for Metabolic Diseases Product Portfolio

6.3.5 Eli Lily Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Company Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi Peptide Drugs for Metabolic Diseases Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Sanofi Peptide Drugs for Metabolic Diseases Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 Huadong Medicine

6.5.1 Huadong Medicine Company Information

6.5.2 Huadong Medicine Description and Business Overview

6.5.3 Huadong Medicine Peptide Drugs for Metabolic Diseases Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Huadong Medicine Peptide Drugs for Metabolic Diseases Product Portfolio

6.5.5 Huadong Medicine Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Peptide Drugs for Metabolic Diseases Industry Chain Analysis

7.2 Peptide Drugs for Metabolic Diseases Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Peptide Drugs for Metabolic Diseases Production Mode & Process Analysis

7.4 Peptide Drugs for Metabolic Diseases Sales and Marketing

7.4.1 Peptide Drugs for Metabolic Diseases Sales Channels

7.4.2 Peptide Drugs for Metabolic Diseases Distributors

7.5 Peptide Drugs for Metabolic Diseases Customer Analysis

8 Peptide Drugs for Metabolic Diseases Market Dynamics

8.1 Peptide Drugs for Metabolic Diseases Industry Trends

8.2 Peptide Drugs for Metabolic Diseases Market Drivers

8.3 Peptide Drugs for Metabolic Diseases Market Challenges

8.4 Peptide Drugs for Metabolic Diseases Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Peptide Drugs for Metabolic Diseases Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Peptide Drugs for Metabolic Diseases Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Peptide Drugs for Metabolic Diseases Market Competitive Situation by Manufacturers in 2024

Table 4. Global Peptide Drugs for Metabolic Diseases Sales (kg) of Key Manufacturers (2020-2025)

Table 5. Global Peptide Drugs for Metabolic Diseases Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Peptide Drugs for Metabolic Diseases Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Peptide Drugs for Metabolic Diseases Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Peptide Drugs for Metabolic Diseases Average Price (US$/g) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Peptide Drugs for Metabolic Diseases, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Peptide Drugs for Metabolic Diseases, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Peptide Drugs for Metabolic Diseases, Product Type & Application

Table 12. Global Key Manufacturers of Peptide Drugs for Metabolic Diseases, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Peptide Drugs for Metabolic Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Drugs for Metabolic Diseases as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Peptide Drugs for Metabolic Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Peptide Drugs for Metabolic Diseases Sales by Region (2020-2025) & (kg)

Table 18. Global Peptide Drugs for Metabolic Diseases Sales Market Share by Region (2020-2025)

Table 19. Global Peptide Drugs for Metabolic Diseases Sales by Region (2026-2031) & (kg)

Table 20. Global Peptide Drugs for Metabolic Diseases Sales Market Share by Region (2026-2031)

Table 21. Global Peptide Drugs for Metabolic Diseases Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Region (2020-2025)

Table 23. Global Peptide Drugs for Metabolic Diseases Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Region (2026-2031)

Table 25. North America Peptide Drugs for Metabolic Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Peptide Drugs for Metabolic Diseases Sales by Country (2020-2025) & (kg)

Table 27. North America Peptide Drugs for Metabolic Diseases Sales by Country (2026-2031) & (kg)

Table 28. North America Peptide Drugs for Metabolic Diseases Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Peptide Drugs for Metabolic Diseases Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Peptide Drugs for Metabolic Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Peptide Drugs for Metabolic Diseases Sales by Country (2020-2025) & (kg)

Table 32. Europe Peptide Drugs for Metabolic Diseases Sales by Country (2026-2031) & (kg)

Table 33. Europe Peptide Drugs for Metabolic Diseases Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Peptide Drugs for Metabolic Diseases Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Peptide Drugs for Metabolic Diseases Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Peptide Drugs for Metabolic Diseases Sales by Region (2020-2025) & (kg)

Table 37. Asia Pacific Peptide Drugs for Metabolic Diseases Sales by Region (2026-2031) & (kg)

Table 38. Asia Pacific Peptide Drugs for Metabolic Diseases Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Peptide Drugs for Metabolic Diseases Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Peptide Drugs for Metabolic Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Peptide Drugs for Metabolic Diseases Sales by Country (2020-2025) & (kg)

Table 42. Latin America Peptide Drugs for Metabolic Diseases Sales by Country (2026-2031) & (kg)

Table 43. Latin America Peptide Drugs for Metabolic Diseases Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Peptide Drugs for Metabolic Diseases Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Peptide Drugs for Metabolic Diseases Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Peptide Drugs for Metabolic Diseases Sales by Country (2020-2025) & (kg)

Table 47. Middle East and Africa Peptide Drugs for Metabolic Diseases Sales by Country (2026-2031) & (kg)

Table 48. Middle East and Africa Peptide Drugs for Metabolic Diseases Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Peptide Drugs for Metabolic Diseases Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Peptide Drugs for Metabolic Diseases Sales (kg) by Type (2020-2025)

Table 51. Global Peptide Drugs for Metabolic Diseases Sales (kg) by Type (2026-2031)

Table 52. Global Peptide Drugs for Metabolic Diseases Sales Market Share by Type (2020-2025)

Table 53. Global Peptide Drugs for Metabolic Diseases Sales Market Share by Type (2026-2031)

Table 54. Global Peptide Drugs for Metabolic Diseases Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Peptide Drugs for Metabolic Diseases Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Type (2020-2025)

Table 57. Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Type (2026-2031)

Table 58. Global Peptide Drugs for Metabolic Diseases Price (US$/g) by Type (2020-2025)

Table 59. Global Peptide Drugs for Metabolic Diseases Price (US$/g) by Type (2026-2031)

Table 60. Global Peptide Drugs for Metabolic Diseases Sales (kg) by Application (2020-2025)

Table 61. Global Peptide Drugs for Metabolic Diseases Sales (kg) by Application (2026-2031)

Table 62. Global Peptide Drugs for Metabolic Diseases Sales Market Share by Application (2020-2025)

Table 63. Global Peptide Drugs for Metabolic Diseases Sales Market Share by Application (2026-2031)

Table 64. Global Peptide Drugs for Metabolic Diseases Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Peptide Drugs for Metabolic Diseases Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Application (2020-2025)

Table 67. Global Peptide Drugs for Metabolic Diseases Revenue Market Share by Application (2026-2031)

Table 68. Global Peptide Drugs for Metabolic Diseases Price (US$/g) by Application (2020-2025)

Table 69. Global Peptide Drugs for Metabolic Diseases Price (US$/g) by Application (2026-2031)

Table 70. Novo Nordisk Company Information

Table 71. Novo Nordisk Description and Business Overview

Table 72. Novo Nordisk Peptide Drugs for Metabolic Diseases Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 73. Novo Nordisk Peptide Drugs for Metabolic Diseases Product

Table 74. Novo Nordisk Recent Developments/Updates

Table 75. AstraZeneca Company Information

Table 76. AstraZeneca Description and Business Overview

Table 77. AstraZeneca Peptide Drugs for Metabolic Diseases Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 78. AstraZeneca Peptide Drugs for Metabolic Diseases Product

Table 79. AstraZeneca Recent Developments/Updates

Table 80. Eli Lily Company Information

Table 81. Eli Lily Description and Business Overview

Table 82. Eli Lily Peptide Drugs for Metabolic Diseases Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 83. Eli Lily Peptide Drugs for Metabolic Diseases Product

Table 84. Eli Lily Recent Developments/Updates

Table 85. Sanofi Company Information

Table 86. Sanofi Description and Business Overview

Table 87. Sanofi Peptide Drugs for Metabolic Diseases Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 88. Sanofi Peptide Drugs for Metabolic Diseases Product

Table 89. Sanofi Recent Developments/Updates

Table 90. Huadong Medicine Company Information

Table 91. Huadong Medicine Description and Business Overview

Table 92. Huadong Medicine Peptide Drugs for Metabolic Diseases Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 93. Huadong Medicine Peptide Drugs for Metabolic Diseases Product

Table 94. Huadong Medicine Recent Developments/Updates

Table 95. Key Raw Materials Lists

Table 96. Raw Materials Key Suppliers Lists

Table 97. Peptide Drugs for Metabolic Diseases Distributors List

Table 98. Peptide Drugs for Metabolic Diseases Customers List

Table 99. Peptide Drugs for Metabolic Diseases Market Trends

Table 100. Peptide Drugs for Metabolic Diseases Market Drivers

Table 101. Peptide Drugs for Metabolic Diseases Market Challenges

Table 102. Peptide Drugs for Metabolic Diseases Market Restraints

Table 103. Research Programs/Design for This Report

Table 104. Key Data Information from Secondary Sources

Table 105. Key Data Information from Primary Sources

Table 106. Authors List of This Report

List of Figures

Figure 1. Product Picture of Peptide Drugs for Metabolic Diseases

Figure 2. Global Peptide Drugs for Metabolic Diseases Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Peptide Drugs for Metabolic Diseases Market Share by Type: 2024 & 2031

Figure 4. Semaglutide Product Picture

Figure 5. Dulaglutide Product Picture

Figure 6. Insulin Glargine Product Picture

Figure 7. Insulin Aspart Product Picture

Figure 8. Liraglutide Product Picture

Figure 9. Others Product Picture

Figure 10. Global Peptide Drugs for Metabolic Diseases Market Value by Application (2020-2031) & (US$ Million)

Figure 11. Global Peptide Drugs for Metabolic Diseases Market Share by Application: 2024 & 2031

Figure 12. Diabetes

Figure 13. Obesity

Figure 14. Others

Figure 15. Global Peptide Drugs for Metabolic Diseases Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Peptide Drugs for Metabolic Diseases Market Size (2020-2031) & (US$ Million)

Figure 17. Global Peptide Drugs for Metabolic Diseases Sales (2020-2031) & (kg)

Figure 18. Global Peptide Drugs for Metabolic Diseases Average Price (US$/g) & (2020-2031)

Figure 19. Peptide Drugs for Metabolic Diseases Report Years Considered

Figure 20. Peptide Drugs for Metabolic Diseases Sales Share by Manufacturers in 2024

Figure 21. Global Peptide Drugs for Metabolic Diseases Revenue Share by Manufacturers in 2024

Figure 22. Global 5 and 10 Largest Peptide Drugs for Metabolic Diseases Players: Market Share by Revenue in Peptide Drugs for Metabolic Diseases in 2024

Figure 23. Peptide Drugs for Metabolic Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 24. Global Peptide Drugs for Metabolic Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 25. North America Peptide Drugs for Metabolic Diseases Sales Market Share by Country (2020-2031)

Figure 26. North America Peptide Drugs for Metabolic Diseases Revenue Market Share by Country (2020-2031)

Figure 27. United States Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Canada Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Europe Peptide Drugs for Metabolic Diseases Sales Market Share by Country (2020-2031)

Figure 30. Europe Peptide Drugs for Metabolic Diseases Revenue Market Share by Country (2020-2031)

Figure 31. Germany Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. France Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. U.K. Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Italy Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Russia Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Asia Pacific Peptide Drugs for Metabolic Diseases Sales Market Share by Region (2020-2031)

Figure 37. Asia Pacific Peptide Drugs for Metabolic Diseases Revenue Market Share by Region (2020-2031)

Figure 38. China Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Japan Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. South Korea Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. India Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Australia Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. China Taiwan Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Southeast Asia Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Latin America Peptide Drugs for Metabolic Diseases Sales Market Share by Country (2020-2031)

Figure 46. Latin America Peptide Drugs for Metabolic Diseases Revenue Market Share by Country (2020-2031)

Figure 47. Mexico Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Brazil Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Argentina Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Colombia Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Middle East and Africa Peptide Drugs for Metabolic Diseases Sales Market Share by Country (2020-2031)

Figure 52. Middle East and Africa Peptide Drugs for Metabolic Diseases Revenue Market Share by Country (2020-2031)

Figure 53. Turkey Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Saudi Arabia Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. UAE Peptide Drugs for Metabolic Diseases Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Global Sales Market Share of Peptide Drugs for Metabolic Diseases by Type (2020-2031)

Figure 57. Global Revenue Market Share of Peptide Drugs for Metabolic Diseases by Type (2020-2031)

Figure 58. Global Peptide Drugs for Metabolic Diseases Price (US$/g) by Type (2020-2031)

Figure 59. Global Sales Market Share of Peptide Drugs for Metabolic Diseases by Application (2020-2031)

Figure 60. Global Revenue Market Share of Peptide Drugs for Metabolic Diseases by Application (2020-2031)

Figure 61. Global Peptide Drugs for Metabolic Diseases Price (US$/g) by Application (2020-2031)

Figure 62. Peptide Drugs for Metabolic Diseases Value Chain

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Peptide Drugs for Diabetes Market Research Report 2024

Global Peptide Drugs for Intestinal Diseases Market Research Report 2025

Global GLP 1 Drug Peptide API Market Research Report 2024

Global Peptide Based Metabolic Disorders Therapeutics Market Research Report 2024

Global GLP 1RA based Therapy for Obesity Market Research Report 2024

Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024

Drugs for Metabolic Disorders Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Weight Loss Drug Market Research Report 2024

Global GLP 1 Weight Loss Pill Market Research Report 2024

Global Drugs for Treating Metabolic Disorders Market Research Report 2024

Metabolic Disorders Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Semaglutide Preparations Market Research Report 2024

Metabolic Disorders Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024

Global Peptide Therapy Market Research Report 2025

Global GLP 1 Agonists for Obesity Market Research Report 2024

GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Weight Loss Injection Market Research Report 2024

Global Metabolism Drugs Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions